{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:54:58Z","timestamp":1792018498094,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clim.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T16:21:24Z","timestamp":1536423684000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1\/2 study"],"prefix":"10.1016","volume":"197","author":[{"given":"Anu","family":"Cherukuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"de Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-8340","authenticated-orcid":false,"given":"Andrea","family":"Van Tuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Slasor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Henshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitayo","family":"Ajayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Schweighardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.09.003_bb0005","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","article-title":"Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis","volume":"277","author":"Sleat","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.clim.2018.09.003_bb0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/302427","article-title":"Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder","volume":"64","author":"Sleat","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.clim.2018.09.003_bb0015","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/clinchem\/46.7.1005","article-title":"Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays","volume":"46","author":"Sohar","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clim.2018.09.003_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13023-016-0414-2","article-title":"Moving towards effective therapeutic strategies for neuronal ceroid lipofuscinosis","volume":"11","author":"Geraets","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2018.09.003_bb0025","first-page":"682","article-title":"CLN2 disease","volume":"13","author":"Kohlsch\u00fctter","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.clim.2018.09.003_bb0030","first-page":"199","article-title":"Epilepsy in neuronal ceroid lipofuscinoses","volume":"3","author":"Kohlsch\u00fctter","year":"2014","journal-title":"J. Pediatr. Epilepsy"},{"key":"10.1016\/j.clim.2018.09.003_bb0035","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1074\/jbc.M412047200","article-title":"Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo","volume":"280","author":"Golabek","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2018.09.003_bb0040","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1074\/jbc.M806943200","article-title":"Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis","volume":"284","author":"Guhaniyogi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2018.09.003_bb0045","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.clim.2018.09.003_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2014.03.005","article-title":"Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution","volume":"277","author":"Vuillemenot","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.clim.2018.09.003_bb0055","article-title":"Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis","volume":"114","author":"Vuillemenot","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2018.09.003_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/mgme.1999.2894","article-title":"Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models","volume":"68","author":"Brooks","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2018.09.003_bb0065","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","article-title":"Enzyme replacement in a canine model of Hurler syndrome","volume":"91","author":"Shull","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2018.09.003_bb0070","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.09.003_bb0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases--the horizon expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clim.2018.09.003_bb0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-015-0262-5","article-title":"Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act","volume":"10","author":"Mechler","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2018.09.003_bb0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"10.1016\/j.clim.2018.09.003_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/8904_2012_192","article-title":"CRIM-negative pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy","volume":"9","author":"Khallaf","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.clim.2018.09.003_bb0095","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clim.2018.09.003_bb0100","first-page":"1","article-title":"Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model","author":"Xue","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.clim.2018.09.003_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.clim.2018.09.003_bb0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1208\/s12248-014-9587-6","article-title":"New FDA draft guidance on immunogenicity","volume":"16","author":"Parenky","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.clim.2018.09.003_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: mechanisms, prediction and reduction","volume":"60","author":"Sethu","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.clim.2018.09.003_bb0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4065\/84.3.268","article-title":"Mechanisms of drug-induced allergy","volume":"84","author":"Schnyder","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clim.2018.09.003_bb0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"Gelder","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.clim.2018.09.003_bb0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.clim.2018.09.003_bb0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2018.09.003_bb0140","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clim.2018.09.003_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jim.2016.10.006","article-title":"Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome","volume":"440","author":"Melton","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2018.09.003_bb0150","first-page":"1781","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.clim.2018.09.003_bb0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3181","article-title":"The quintessence of immunogenicity reporting for biotherapeutics","volume":"33","author":"Shankar","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2018.09.003_bb0160","first-page":"335","article-title":"Immunologic responses to therapeutic biologic agents","volume":"18","author":"Purcell","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clim.2018.09.003_bb0165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40264-015-0285-9","article-title":"Chimeric fusion proteins used for therapy: indications, mechanisms, and safety","volume":"38","author":"Baldo","year":"2015","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.clim.2018.09.003_bb0170","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","article-title":"Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics","volume":"18","author":"Wu","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.clim.2018.09.003_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-015-0255-4","article-title":"Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome","volume":"10","author":"Pal","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2018.09.003_bb0180","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","article-title":"Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy","volume":"97","author":"Saif","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2018.09.003_bb0185","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1081-1206(10)62890-6","volume":"83","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clim.2018.09.003_bb0190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ymgme.2018.02.011","article-title":"Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5years of treatment","volume":"123","author":"Hendriksz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2018.09.003_bb0195","first-page":"S100","article-title":"Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders","volume":"47","author":"Miebach","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2018.09.003_bb0200","first-page":"570","article-title":"Immunobiology of the blood-brain barrier","volume":"5","author":"Miller","year":"1999","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.clim.2018.09.003_bb0205","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1038\/srep04422","article-title":"Immune privilege of the CNS is not the consequence of limited antigen sampling","volume":"4","author":"Harris","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2018.09.003_bb0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbi.2006.11.012","article-title":"Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions","volume":"21","author":"Carson","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.clim.2018.09.003_bb0215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000446154","article-title":"IgE-mediated hypersensitivity and desensitisation with recombinant enzymes in pompe disease and type i and type vi mucopolysaccharidosis","volume":"169","author":"Capanoglu","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.clim.2018.09.003_bb0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2018.09.003_bb0225","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.clim.2018.09.003_bb0230","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses","volume":"2","author":"Baldo","year":"2013","journal-title":"Oncoimmunology"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618302171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618302171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T07:55:15Z","timestamp":1604908515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618302171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":46,"alternative-id":["S1521661618302171"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.09.003","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1\/2 study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}